FCA Perils Mount For Drugmakers As DOJ Gets Personal
The U.S. Department of Justice is increasingly pushing to directly monitor drugmakers long after False Claims Act cases are closed and hold executives personally liable for future misconduct, a development that...To view the full article, register now.
Already a subscriber? Click here to view full article